Journal of Clinical Oncology, Vol 5, 574-578, Copyright © 1987 by American Society of Clinical Oncology

ARTICLES

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma

D Glover, JH Glick, C Weiler, K Fox and D Guerry

Cisplatin, alone or in combination with other chemotherapeutic agents, is relatively inactive against metastatic melanoma. Prior trials have demonstrated partial response (PR) rates of less than 10% with cisplatin alone. WR-2721 is an organic thiophosphate compound, which in the animal model, selectively protects normal tissues against the toxicity of cisplatin chemotherapy. During the course of a phase I trial of WR-2721 and cisplatin, objective PRs were noted in patients with far advanced metastatic melanoma. These observations led us to perform a phase II trial of WR-2721 and cisplatin. Thirty-six patients received 128 courses of WR-2721 before cisplatin (60 to 150 mg/m2). All patients had progressive disease before treatment. Objective PRs were observed in 19 of 36 evaluable patients (53%). Three additional patients had minor responses (MRs). PRs occurred in 53% of patients with prior chemotherapy (ten of 19). Sites of responding metastases were subcutaneous disease (15 of 19 patients), lymph nodes (16 of 21 patients), lung (four of ten patients), and liver (eight of 17 patients). The median duration of response was 4 months, with a mean of 4.5 months (range, 1 to 8 months). Transient nephrotoxicity was observed in less than 5% of courses. In all cases, renal function returned to normal within 1 to 2 weeks. Hematologic toxicity was mild and infrequent. Nine patients developed peripheral neuropathy following a median cisplatin dose of 670 mg/m2. Twenty patients experienced mild clinical hearing loss. These data suggest that WR-2721 may potentiate the antitumor activity of cisplatin in metastatic melanoma.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. M. Kokkinakis, A. G. Brickner, J. M. Kirkwood, X. Liu, J. E. Goldwasser, A. Kastrama, C. Sander, D. Bocangel, and S. Chada Mitotic Arrest, Apoptosis, and Sensitization to Chemotherapy of Melanomas by Methionine Deprivation Stress Mol. Cancer Res., August 1, 2006; 4(8): 575 - 589. [Abstract] [Full Text] [PDF]

				D. H. Moore, J. Donnelly, W. P. McGuire, L. Almadrones, D. F. Cella, T. J. Herzog, and S. E. Waggoner Limited Access Trial Using Amifostine for Protection Against Cisplatin- and Three-Hour Paclitaxel-Induced Neurotoxicity: A Phase II Study of the Gynecologic Oncology Group J. Clin. Oncol., November 15, 2003; 21(22): 4207 - 4213. [Abstract] [Full Text] [PDF]

				D. Lorusso, G. Ferrandina, S. Greggi, A. Gadducci, S. Pignata, S. Tateo, R. Biamonte, L. Manzione, G. Di Vagno, F. Ferrau', et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients Ann. Onc., July 1, 2003; 14(7): 1086 - 1093. [Abstract] [Full Text] [PDF]

				K. Jahnukainen, T. Jahnukainen, T. T. Salmi, K. Svechnikov, S. Eksborg, and O. Soder Amifostine Protects against Early but not Late Toxic Effects of Doxorubicin in Infant Rats Cancer Res., September 1, 2001; 61(17): 6423 - 6427. [Abstract] [Full Text] [PDF]

				M. L. Hensley, L. M. Schuchter, C. Lindley, N. J. Meropol, G. I. Cohen, G. Broder, W. J. Gradishar, D. M. Green, R. J. Langdon Jr, R. B. Mitchell, et al. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants J. Clin. Oncol., October 1, 1999; 17(10): 3333 - 3355. [Abstract] [Full Text] [PDF]

				M. Summerhayes Review : Amifostine and other chemoprotective agents in cancer chemotherapy: A brief review Journal of Oncology Pharmacy Practice, December 1, 1995; 1(4): 21 - 31. [Abstract] [PDF]

				H. J. Durivage and N. L. Burnham Prevention and Management of Toxicities Associated With Antineoplastic Drugs Journal of Pharmacy Practice, January 1, 1991; 4(1): 27 - 48. [PDF]

				L. E. Davis Long-Term Complications of Antineoplastic Agents Journal of Pharmacy Practice, January 1, 1991; 4(2): 131 - 150. [PDF]